Moayednia M, Dehghani L, Safi A, Shaygannejad V, Sohrabi K, Rezvani M, et al . The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica. BCN 2021; 12 (2) :199-204
URL:
http://bcn.iums.ac.ir/article-1-1308-en.html
1- Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Department of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:
Introduction: Midkine (MK), a heparin-binding growth factor, is involved in neurological diseases by mediating the inflammatory responses through enhancing the leukocyte migration. The present study assesses the serum concentration of this growth factor among newly developed Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) patients.
Methods: The present research, as a cross-sectional study, was performed at Isfahan University of Medical Sciences, Isfahan City, Iran. All samples were selected from patients who visited Kashani and Alzahra hospitals for two years (2014 to 2016). The MK level was assessed in 80 new MS cases, 80 NMO patients, and 80 healthy subjects. After collecting blood sera samples, MK serum level was measured using the ELISA. The obtained data were analyzed in SPSS.
Results: The Mean±SD MK level was 1038.58±44.73 pg/mL in the MS group, which was significantly higher than the Mean±SD MK level in the NMO (872.62±55.42 pg/mL) and control groups (605.02±9.42 pg/mL).
Conclusion: Overall, these results demonstrated that MK plays a prominent role in inflammatory reactions and neuroautoimmune diseases, especially in MS. So, the MK level may be used for earlier diagnosis and also prevention of disease progression by using a special inhibitor.
Full-Text [PDF 2256 kb]
| |
Full-Text (HTML)
Highlights
● The mean Midkine (MK) level in Multiple Sclerosis (MS) patients is higher than Neuromyelitis Optica (NMO) patients and the healthy control group.
● The level of MK is higher in the NMO group compared with the healthy one.
● The healthy subjects have the lowest mean of MK level compared with the other groups.
● Sex and age have no significant association with the MK level.
Plain Language Summary
Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) are two distinct diseases with similar clinical symptoms, so it is necessary to distinguish these disorders from each other. Although there are many studies to find biomarkers for this goal, only a few of them have been validated for routine clinical practice. Because of the inflammatory nature of MS and NMO, our research group claims to evaluate the utility of Midkine (MK) as a heparin-binding growth factor that is implicated in inflammation. Our results demonstrated that MS patients have higher MK levels compared to NMO patients and the healthy participants. Also, sex and age have no significant association with the MK level. Therefore, MK may be a reliable biological marker in differentiating between MS and NMO.
Type of Study:
Original |
Subject:
Clinical Neuroscience Received: 2019/08/15 | Accepted: 2020/02/25 | Published: 2021/03/1